Moolec Science (MLECW) Change in Receivables (2022 - 2024)
Moolec Science (MLECW) posted Change in Receivables of -$1.4 million for Q4 2024, down 2257.48% sequentially from -$58061.0 in Q3 2024, and down 1494.85% YoY from $98131.0 in Q1 2024.
Moolec Science (MLECW) Change in Receivables (2022 - 2024) Analysis & Trends
Moolec Science has reported Change in Receivables for 3 years, with the latest figure at -$1.4 million in Q4 2024.
- Quarterly Change in Receivables fell 1494.85% year-over-year to -$1.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$42.6 million (down 16.01% YoY) and the FY2025 annual result came in at $26.0 million, up 163.12% from the prior year.
- Change in Receivables eased to -$1.4 million in Q4 2024 per MLECW's latest filing, from -$58061.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $98131.0 in Q4 2023 and troughed at -$41.0 million in Q2 2024.
- A 3-year average of -$7.2 million and a median of -$146394.0 in 2023 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 7069.53% in 2023, down 543893.6% in 2023.
- Over 3 years, Change in Receivables stood at -$1408.0 in 2022, then jumped by 7069.53% to $98131.0 in 2023, then plunged by 1494.85% to -$1.4 million in 2024.
- According to Business Quant data, Change in Receivables over the past three periods registered -$1.4 million, -$58061.0, and -$41.0 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.37 Mn |
| Dec 31, 2024 | -1.37 Mn |
| Sep 30, 2024 | -58,061.00 |
| Sep 30, 2024 | -58,061.00 |
| Jun 30, 2024 | -41.05 Mn |
| Jun 30, 2024 | -41.05 Mn |
| Mar 31, 2024 | -162,073.00 |
| Mar 31, 2024 | -162,073.00 |
| Dec 31, 2023 | 98,131.00 |
| Dec 31, 2023 | 98,131.00 |
| Sep 30, 2023 | -146,394.00 |
| Sep 30, 2023 | -146,394.00 |
| Jun 30, 2023 | -35.77 Mn |
| Jun 30, 2023 | -35.77 Mn |
| Mar 31, 2023 | -935,325.00 |
| Mar 31, 2023 | -935,325.00 |
| Dec 31, 2022 | -1,408.00 |
| Dec 31, 2022 | -1,408.00 |
| Sep 30, 2022 | -407.00 |
| Sep 30, 2022 | -407.00 |